Niladri Aichbhaumik, MD
Allergy & Immunology · Saint Paul, MNNPI 1437379369
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by CSL Behring at 38.0% of the total.
Across 160 payments — averaging $92.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$6K
- Shire North American Group Inc$4K
- Blueprint Medicines Corporation$1K
- Biocryst US Sales Co., LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$955
- Pharming Healthcare, Inc.$227
- plus $2K from 32 others
Across 2 payments — averaging $26,600 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$53K
What the payments were for
- Consulting fees$7,97754%
- Speaking & faculty fees$2,94120%
- Travel & lodging$1,1398%
- Food & beverage$2,62518%
- Education$871%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 25 | $5,606 |
| Shire North American Group Inc | 7 | $3,944 |
| Blueprint Medicines Corporation | 3 | $1,348 |
| Biocryst US Sales Co., LLC | 10 | $1,022 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $955 |
| Pharming Healthcare, Inc. | 7 | $227 |
| Amgen(2 entities) | 14 | $225 |
| Regeneron Healthcare Solutions, Inc. | 11 | $184 |
| Sanofi | 12 | $183 |
| Phadia US Inc. | 7 | $141 |
| GSK | 7 | $133 |
| Teva Pharmaceuticals USA, Inc. | 7 | $112 |
| AstraZeneca | 6 | $83 |
| Ionis Pharmaceuticals, Inc. | 3 | $65 |
| LEO Pharma Inc. | 3 | $58 |
| Pfizer | 3 | $43 |
| Cycle Pharmaceuticals Inc | 2 | $42 |
| Optinose US, Inc. | 2 | $36 |
| Genentech USA, Inc. | 1 | $25 |
| Philips North America LLC | 2 | $25 |
| Alk-abello, Inc | 1 | $24 |
| Stryker | 1 | $22 |
| Incyte Corporation | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Octapharma USA, Inc. | 1 | $21 |
| Insmed, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Novartis | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 2 | $16 |
| Kaleo, Inc. | 1 | $14 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| AbbVie | 1 | $13 |
| Circassia Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Aimmune Therapeutics, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,769 in reported general payments places this provider in the 85th percentile of 57 allergy & immunology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 13 | $682,503 |
| Dupixent PenDupilumab | 19 | $90,132 |
| XolairOmalizumab | 13 | $72,199 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $26,151 |
| Arnuity ElliptaFluticasone Furoate | 51 | $21,489 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $15,064 |
| Mometasone Furoate | 98 | $13,741 |
| Qvar RedihalerBeclomethasone Dipropionate | 31 | $13,557 |
| Spiriva RespimatTiotropium Bromide | 16 | $11,439 |
| Fluticasone Propionate HfaFluticasone Propionate | 33 | $11,204 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $9,107 |
| Azelastine Hcl | 225 | $7,227 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $6,656 |
| Pulmicort FlexhalerBudesonide | 15 | $6,626 |
| DuleraMometasone/Formoterol | 16 | $5,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $955 | $682,50313 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $133 | $47,64090 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $112 | $13,55731 claims |
| Boehringer IngelheimSpiriva Respimat | $13 | $11,43916 claims |
| AstraZenecaPulmicort Flexhaler, Symbicort | $83 | $10,17428 claims |
| MerckDulera, Asmanex | $19 | $9,90031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 57 allergy & immunology providers in Minnesota.
Other allergy & immunology in Saint Paul
- Nicole ChaseSaint Paul$1.8M
- Roula AltishehSaint Paul$468
- Timothy LindSaint Paul$375
- Micah KarasovSaint Paul$145
- John WahlstromSaint Paul$79
- Jason RaaschPlymouth$153K
- Thanai PongdeeRochester$58K
- Elina JerschowRochester$45K
- Nancy OttMinneapolis$23K
- David LoweRochester$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.